Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Relapsed/Refractory Classical Hodgkin's Lymphoma
NCT00742027Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in Classical Hodgkin Lymphoma (cHL), sponsored by Novartis. Primary endpoint: Objective Response Rate at 32 weeks. Started Sep 2008; status: completed.
02
Drugs
panobinostat
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT00742027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742027.